Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2018 | Exhaled breath signatures for lung cancer detection: the LuCID study

There is a growing need to improve the early diagnosis of lung cancer; non-invasive, quick and accessible assays would greatly aid in this. In this interesting interview, Robert Rintoul, PhD, FRCP, of the Cancer Research UK Cambridge Institute, Cambridge, UK, discusses the exciting work that he is involved with, investigating volatile organic compounds in the breath in order to identify exhaled breath signatures for lung cancer. This work is being undertaken in the Lung Cancer Indicator Detection (LuCID; NCT02612532) study, a multi-centre prospective trial for lung cancer screening. Dr Rintoul gives an overview of the promising trial, which has recruited a large cohort, and highlights the utility of this type of test in determining whether borderline nodules identified on CT scans are cancerous. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.